Tag: Oncology

First Dose of Inovio’s dMAb™ Technology

Inovio Pharmaceuticals, Inc. in collaboration with The Wistar Institute and the University of Pennsylvania announced that the first subject was dosed as part of the first-ever human study of Inovio's ...

Anixa, Wistar Institute and Dmitry I. Gabrilovich Focus on MDSC

Anixa Biosciences, Inc., a biotechnology company focused on using the body's immune system to fight cancer, today announced it has extended its collaboration with The Wistar Institute and Dmitry I. Ga...

NICE Recommends Roche’s Breast Cancer Drug for Post-Surgery

NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes. This positiv...

3SBio and Verseau Partners in Immuno-Oncology Field

3SBio Inc. and Verseau Therapeutics, Inc. have announced a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a b...

NeoTX in Clinical Collaboration with AstraZeneca

astrazeneca
NeoTX Therapeutics, Ltd announced that it has entered into a clinical collaboration with AstraZeneca Group Plc global biologics research and development arm, MedImmune, to support Phase 1b/2 studies i...

Grey Wolf to Fund Development of Therapy Increasing Tumour Visibility

Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system. Grey Wolf Therapeutics, a drug discovery ...

First Drug for Rare Cancer under Priority Review

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT). The Ja...

GSK and Merck to Develop Cancer Treatment under €3.7bn Deal

GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal. The M7824 is an investigational bifunctional fusion protein im...

Developing Treatments for OAC

Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail, unveiling good news that more than half could be targeted by drugs currently already in trials for other...

Roche Plans to Expand Use of its Breast Cancer Drug

Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla (trastuzumab emtansine) to include the adjuvant treatment of people with HER2-positive e...

Repare Therapeutics’ Polθ Inhibitor Heads for Asia

Repare Therapeutics, Inc., a privately held precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in clearly defined pa...

Searching for CAR-T Combinations to Tackle Tumours

Getting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a conference heard details of a cutting-edge approach that could inform clinical trials in the future. Kisaco Rese...

Basilea Collaborates with Roche to Explore Urothelial Cancer Drugs

ArQule, Inc.’s partner, Basilea Pharmaceutica Ltd., announced that it entered into a collaboration with Roche to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkp...

First China’s P4P Program for Cancer by Pfizer

Pfizer Inc. launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The program is the nation's first pay-for-performance insurance for oncology and c...

FDA Approved Genetic Health Risk Report for Inherited Cancers

The second ever direct-to-consumer genetic health risk report for inherited cancers was just approved by the US Food and Drug Administration (FDA). Soon, consumers can see if they carry the genes resp...

Acrotech to Acquire 7 FDA-Approved Spectrum’s Drugs

Aurobindo Pharma’s subsidiary Acrotech Biopharma has agreed to acquire seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in a deal valued at around $300m. Under the deal...